Radio and PodcastRadio and PodcastLive Radio & Podcasts
KEYNOTE-006 Study 10-Year Survival Data Confirm PD-L1 Checkpoint Inhibition Best for Patients With Advanced Melanoma artwork
Science & Medicine

KEYNOTE-006 Study 10-Year Survival Data Confirm PD-L1 Checkpoint Inhibition Best for Patients With Advanced Melanoma

Oncology Times - OT Broadcasts from the iPad Archives by Oncology Times

Jan 25, 20257:33Science & Medicine

The pivotal role of programmed death-ligand 1 (PD-L1) checkpoint inhibition for treating advanced melanoma has been confirmed in findings from the KEYNOTE-006 study comparing the anti-PD-L1 antibody pembrolizumab immunot...

Related Episodes

Continue listening to more episodes from Oncology Times - OT Broadcasts from the iPad Archives.